Breaking News

Galapagos Receives GSK Milestone

January 11, 2013

Delivers fifth drug candidate

Galapagos NV has delivered a fifth preclinical drug candidate in its alliance with GlaxoSmithKline, triggering a milestone payment to Galapagos. The drug discovery and development alliance dates back to 2006.
 
"Galapagos has identified five candidate drugs, of which two have been in-licensed by GSK to date," said Onno van de Stolpe, chief executive officer of Galapagos. "We hope that more programs from this alliance may enter the clinic."
 
Subject to achievement of certain milestones Galapagos has the potential to receive more than $270 million in total milestone payments, as well as royalties. GSK has an exclusive option to further develop and commercialize compounds from the alliance on a worldwide basis.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers